SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Viking Therapeutics, Inc. (VKTX)

The trial was slated to enroll more than

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
ZeWaffleBaron Member Profile
 
Followed By 7
Posts 150
Boards Moderated 0
Alias Born 04/26/17
160x600 placeholder
Securities Registration Statement (s-1) "Edgar (US Regulatory)" - 10/17/2017 4:49:11 PM
Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleuko... "PR Newswire (US)" - 10/4/2017 7:05:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/29/2017 4:46:11 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/29/2017 7:06:35 AM
Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital "PR Newswire (US)" - 9/29/2017 7:05:00 AM
Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settin... "PR Newswire (US)" - 9/25/2017 7:30:00 AM
Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatit... "PR Newswire (US)" - 9/11/2017 7:05:00 AM
Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease ... "PR Newswire (US)" - 9/7/2017 7:02:00 AM
Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference "PR Newswire (US)" - 9/5/2017 7:30:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/9/2017 5:04:19 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/9/2017 4:17:47 PM
Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update "PR Newswire (US)" - 8/9/2017 4:05:00 PM
Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 "PR Newswire (US)" - 8/2/2017 7:30:00 AM
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture "PR Newswire (US)" - 7/12/2017 7:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/6/2017 8:11:19 AM
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors "PR Newswire (US)" - 7/6/2017 8:00:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 6/27/2017 4:31:03 PM
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 6/22/2017 4:38:53 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/19/2017 4:33:42 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 6/15/2017 5:15:32 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/14/2017 10:02:28 AM
Viking Therapeutics Announces $4.3 Million Registered Direct Offering "PR Newswire (US)" - 6/14/2017 9:55:00 AM
Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) "PR Newswire (US)" - 6/6/2017 7:14:00 AM
Viking Therapeutics to Present at Upcoming Investor Conferences "PR Newswire (US)" - 5/31/2017 7:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/24/2017 4:18:06 PM
ZeWaffleBaron   Wednesday, 10/04/17 06:43:29 AM
Re: zoomlik post# 697
Post # of 892 
The trial was slated to enroll more than that, and they chose to complete enrollment with the current number. This was a decent length trial, they should have had plenty of time for interim analyses of data. You feel that they mistakenly stopped early and will not have statistically significance, and that will be the error?! Lol! I've worried about many things in this space, but that ain't one of them. Do some DD before you throw your money somewhere. I doubt you are worrying here for free tho

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist